All News

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Systems now available at a reduced list price of $5,850.

Involvement with the organizations and nonprofit foundations that focus on specialty disease states can help specialty pharmacists gain perspective on the patients they treat.

Crizanlizumab (SEG101, Novartis) is being developed to prevent painful complications called vaso-occlusive crises in patients with sickle cell disease.

Study suggests a new therapy could stop tumor growth by affecting myeloid cell behavior.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Community-acquired pneumonia is a major cause of mortality and morbidity among patients with HIV.

Health care costs in the US represent nearly 20% of the GDP.

Is your life how you imagined it would be, or is it, in reality, more complicated and stressful than you planned? Do you wonder how you managed to achieve all you did including all the patient contacts, and fielding the calls from doctors, too?

A multimethod approach including use of refill data may be the most effective method to identify nonadherence in young patients with chronic kidney disease.

Advancements in cancer therapy have improved survival time for patients with non-small cell lung cancer (NSCLC), according to a new study published in the Journal of Thoracic Oncology.

Controlling the viral reaction of cells latently infected with HIV may have implications for future drug treatments.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

A substantial portion of mortality from liver cirrhosis and hepatocellular carcinoma can be attributed to the extrahepatic manifestations associated with hepatitis C virus.

Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials.